| |
Mild cognitive impairment and Alzheimer’s
April 1, 2008
New technologies help determine whether cognitive impairment will lead to Alzheimer’s, from the Harvard Mental Health Letter
With nearly 10 million baby boomers at risk for developing Alzheimer’s disease, researchers are taking a closer look at a condition known as mild cognitive impairment. This is a state between the normal forgetfulness that comes with aging and the more pronounced thinking deficits of dementia. Mild cognitive impairment often progresses to Alzheimer’s disease, but some people remain stable and others recover. New technology is improving the ability to determine who might fall into each category, reports the April 2008 issue of the Harvard Mental Health Letter. These developments are promising because they are occurring just as the first disease-modifying drugs for Alzheimer’s have reached late-stage clinical testing.
One technology, fluorodeoxyglucose positron emission tomography (FDG-PET), measures blood glucose metabolism in the cerebral cortex. Diminished glucose uptake suggests that neurons are not as active. Clinicians can also measure brain volume changes with volumetric MRI to detect shrinkage, which is typical in Alzheimer’s. These techniques are likely to prove most useful when combined with detection of newly discovered proteins believed to be the first signs of Alzheimer’s.
If one of these technologies—or a combination—can reliably predict which people with cognitive impairment are likely to progress to Alzheimer’s, scientists might be able to determine who should get the disease-modifying medications now in development. And they might be able to predict which healthy people are most likely to get mild cognitive impairment, and try to prevent it.
The technologies and medications needed to predict and prevent mild cognitive impairment and Alzheimer’s are still in the early stages of development, but the Harvard Mental Health Letter says that this research will almost certainly lead to better treatments.
Also in this issue:
- Preschoolers with psychiatric disorders
- Post-combat mental health help
- Asthma and anxiety, depression
- Metformin plus lifestyle changes help people with schizophrenia lose weight
- Antidepressant effectiveness
 Related
Information
Harvard Mental Health Letter is available
from Harvard Health Publications, the publishing division
of the Harvard Medical School. You can subscribe at www.health.harvard.edu/mental or
by calling 1-877-649-9457 toll-free.
About Harvard Health Publications
Harvard Health
Publications publishes five monthly newsletters—Harvard
Health Letter, Harvard
Women's Health Watch, Harvard
Men's Health Watch, Harvard
Mental Health Letter, and Harvard
Heart Letter—as well as more than 50 special
health reports and books drawing on the expertise of
the 8,000 faculty physicians at Harvard Medical School
and its world-famous affiliated hospitals. For more
information about Harvard Medical School publications,
please visit our Web site, www.health.harvard.edu.
Source: Harvard
Health Publications
Contact: hhpmedia@hms.harvard.edu
Web site: http://www.health.harvard.edu |
|
Printed
Version:
